Biotech Has the Best Returns. We Make Them Accessible.
Phase 3 data. FDA approvals. Breakthrough designations. These events regularly move stocks 50-200%. Most investors avoid them because the science is too complex. We built the AI to change that.
Our Mission
We believe biotech's highest-reward opportunities shouldn't be locked behind institutional walls. Our mission is to democratize biotech research—giving retail investors the same clarity that hedge funds have, without the $25,000 terminal or PhD in molecular biology.
We're making an opaque industry transparent, one company at a time. Because informed investors make better decisions—and everyone deserves access to the information they need.
The Biotech Opportunity Most Investors Miss
The Problem
- Biotech companies cure cancer, yet retail investors avoid them
- Clinical trial data reads like a foreign language
- Wall Street analysts have PhD teams—you have Google
- By the time you understand the news, the stock already moved
The Opportunity
- Fewer retail investors = less efficient market = more opportunity
- Binary events (trial results, FDA decisions) create massive moves
- AI can now do what took PhD teams weeks
- Early understanding = early positioning = outsized returns
Research That Anyone Can Understand
Our AI doesn't just summarize—it translates. It reads FDA documents, clinical trial protocols, and scientific papers, then explains them in plain English with clear investment implications.
When a company announces:
"Statistically significant p<0.001 with durable complete response"
Our AI tells you:
"The drug worked better than expected. Here's what that means for the stock."
You're an Investor, Not a Scientist. We Get It.
We built FuzeBio for people who want biotech returns without becoming biotech experts. Every feature is designed to answer the questions that matter to your portfolio:
Is this stock undervalued?
What events could move it and when?
What's the bull case? The bear case?
What do I need to watch?
No jargon. No assumptions about your background. Just clear answers.
Know the Space? Go Deeper.
If you're already comfortable with biotech, FuzeBio doesn't slow you down with basics—it accelerates your workflow.
Adjust probability of success assumptions on individual pipeline drugs. Stress-test valuations across discount rate scenarios. Compare pipeline depth across competitors side-by-side. Export your analysis.
Everything you'd build in Excel, generated instantly and updated in real-time. Spend your time on conviction, not data gathering.
Data sourced from SEC EDGAR, ClinicalTrials.gov, FDA databases, and real-time market feeds. Valuation methodology mirrors institutional sell-side standards.
AI-Powered Valuation & Price Targets
Stop guessing what a biotech is worth. Our AI agents generate institutional-grade valuations in real-time— using the same methodologies that hedge funds use: risk-adjusted NPV for pipeline drugs, discounted cash flow analysis, and comparable company multiples.
The best part? Every assumption is adjustable. Change peak sales estimates, probability of success, or discount rates—and watch the price target update in real-time. Build conviction in your own numbers.
Research by Disease
Go beyond individual companies. Our disease research pages give you a complete view of treatment landscapes— see all the players, market potential, and competitive dynamics for conditions like Alzheimer's, obesity, oncology, and more.
Research tools built for clarity
Real-Time Price Targets
Institutional-grade valuation models—rNPV, DCF, and comparables—generated on-demand. Adjust peak sales, probabilities, and discount rates to test your own scenarios.
Science, Translated
Complex mechanisms of action and trial endpoints become clear, investable insights. We don't dumb it down—we make it accessible.
Always Current
Our AI researches on-demand, pulling from the latest sources. No stale databases—just what's happening now.
The Full Picture
Pipeline stages, catalyst calendars, financials, competitive landscape—all in one place, structured for decision-making.
Built for Decisions
Bull and bear cases, probability assessments, and clear thesis statements. Everything you need to make informed calls.
How It Works
You Search
Enter any biotech ticker and our AI agents get to work.
We Research
Our agents scan the same sources you would—SEC filings, ClinicalTrials.gov, press releases, PubMed, and more.
You Decide
Get structured insights in plain English—so you can make informed decisions, not educated guesses.
Our agents access the same public information available to institutional investors: regulatory filings, clinical trial databases, scientific publications, company announcements, and financial data. The difference is how we present it—translated, structured, and ready for decisions.
Who We Are
15+ years of biotech investing experience combined with AI expertise. We've built the tool we wished we had—institutional research quality at a price any investor can afford.
Biotech Moves Fast
Top performers over the past 3 months
Past performance does not guarantee future results. For informational purposes only.
Ready to Add Biotech to Your Portfolio?
The complexity was always the barrier. We removed it.